3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Pheochromocytoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Mesothelioma, Malignant
1
Medulloblastoma
1
Liver Neoplasms
1
Hyperglycemia
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Adrenocortical Carcinoma
1
Adenocarcinoma, Follicular
1
Interventions
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
Vildagliptin
1
Tamoxifen
1
Olanzapine
1
Metformin
1
Letrozole
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Tamoxifen
×
Endocrine
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled